AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26375604
Drug: Capsule formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulations with hydroxypropyl methylcellulose (HPMC)
Trial: 26375604
Drug: Capsule formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulations with magnesium stearate
Trial: 26375604
Drug: Cimetidine commercial
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine commercial solution containing sorbitol
Trial: 26375604
Drug: Capsule formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulations with lower amounts of HPMC and magnesium stearate
Trial: 26375604
Drug: Sorbitol-containing commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol-containing commercial solution
Trial: 26375604
Drug: Sorbitol-free solution
RxNorm normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbitol-free solution
Trial: 19717185
Drug: Bivalirudin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion)
Trial: 19717185
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus GPI (control)
Trial: 18003960
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m² initial dose followed by 250 mg/m² weekly) plus best supportive care
Trial: 9557929
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills (ethinyl-oestradiol plus levonorgestrel)
Trial: 31552577
Drug: Carfilzomib-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib-based therapy
Trial: 31552577
Drug: Daratumumab-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab-based therapy
Trial: 17539852
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids and long-acting beta(2)-agonists
Trial: 16252738
Drug: Used needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used needle penetration in buccal mucosa (women)
Trial: 16252738
Drug: Used needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used needle penetration in buccal mucosa (men)
Trial: 12030995
Drug: Premedication with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with morphine, atropine and suxamethonium
Trial: 100624
Drug: Trimethoprim-sulfamethoxazole (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (4 tablets: trimethoprim 320 mg, sulfamethoxazole 1,600 mg) twice daily for two days
Trial: 100624
Drug: Ampicillin (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (3.5 g) plus probenecid (1 g) in a single dose
Trial: 16485612
Drug: Yoga for
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga for children (in children undergoing pharmacotherapy)
Trial: 29696643
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and ritonavir combination
Trial: 11920976
Drug: CBT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT and antidepressant medication
Trial: 10464889
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg twice daily for 7 days)
Trial: 10464889
Drug: Co-amoxiclav (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (625 mg three times daily for 7 days)
Trial: 7605757
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 0.125% bupivacaine plain solution (group B)
Trial: 7605757
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 0.125% bupivacaine with 75 micrograms clonidine (group B + C)
Trial: 2194767
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (20 mg, up to 10 squares/day)
Trial: 7395237
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg mesterolone per day for 8 weeks
Trial: 28699832
Drug: Placebo stimulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo stimulant medication
Trial: 23649919
Drug: Endotracheal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotracheal lidocaine (3 ml 4% lidocaine via LITA tube)
Trial: 23649919
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil alone (control group)
Trial: 16469151
Drug: CHO drink
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO drink (75 g glucose and 93 g Polyjoule, 2732 kJ, 653 kcal)
Trial: 16469151
Drug: High-fat drink
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat drink (88% fat, cream blended with milk, 2732 kJ, 653 kcal)
Trial: 6178282
Drug: Imipramine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine, 1 mg/kg per day, increased by 1 mg/kg every other day until suppression of ventricular premature complexes or maximum dose of 5 mg/kg per day.
Trial: 6178282
Drug: Imipramine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine, 5 mg/kg per day.
Trial: 6178282
Drug: Imipramine (parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (parent compound).
Trial: 25997544
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg febuxostat
Trial: 25997544
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg febuxostat
Trial: 25997544
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (80 mg)
Trial: 25997544
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (40 mg)
Trial: 21776838
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of liquid culture of Neocallimastix sp. CF 17 (about 10(6) TFU/ml)
Trial: 21776838
Drug: Control (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (200 ml of autoclaved culture)
Trial: 11522112
Drug: Spread enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spread enriched with plant sterols (1.6 g/day)
Trial: 26756502
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg, 2 mL)
Trial: 25885409
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of low dose Iohexol (CILDI) at 0.5 mL/h for 12 h
Trial: 15475831
Drug: enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril (20 mg/d)
Trial: 12062537
Drug: Subcutaneous melagatran
RxNorm normalized name: melagatran
DrugBank: Melagatran (DB13616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous melagatran (1.5‐6 mg bid) in poloxamer depot formulation
Trial: 12062537
Drug: Subcutaneous melagatran
RxNorm normalized name: melagatran
DrugBank: Melagatran (DB13616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous melagatran (2‐4 mg bid) in saline or as a depot formulation in cyclodextrin
Trial: 7594671
Drug: 3, 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3, 10, or 30 micrograms of OspA vaccine
Trial: 7594671
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of OspA vaccine
Trial: 2150644
Drug: Isradipine 2.5mg
RxNorm normalized name: ISRADIPINE 2.5MG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5mg twice daily
Trial: 2150644
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard 20mg twice daily
Trial: 533222
Drug: Atropine 0.1
RxNorm normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.1 mg/10 kg (A)
Trial: 533222
Drug: Atropine 0.1
RxNorm normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.1 mg/10 kg and diazepam 5 mg (AD)
Trial: 533222
Drug: Atropine 0.1
RxNorm normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.1 mg/10 kg and fentanyl 0.2 mg (AF)
Trial: 533222
Drug: Atropine 0.1
RxNorm normalized name: ATROPINE 0.13/PHENOBARBITAL 15MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.1 mg/10 kg, diazepam 5 mg and fentanyl 0.2 mg (ADF)
Trial: 28338546
Drug: Riluzole (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (50-200 mg/d)
Trial: 19622188
Drug: Soya-based cheese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya-based cheese (45.97 mg isoflavones) taken once a day for 10 days under Western diet
Trial: 15112863
Drug: Desloratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine (10 mg/2 tablets)
Trial: 8187784
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg orally twice a day for 7 days)
Trial: 8187784
Drug: Ceftriaxone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (3 g parenterally per day for 7 days)
Trial: 30865001
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 0.11 mg/kg (D1 group)
Trial: 30865001
Drug: Co-administered intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administered intravenous dexamethasone 0.11 mg/kg and intravenous dexmedetomidine 1.0 μg/kg (D2 group)
Trial: 30865001
Drug: Intravenous 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9% saline (control)
Trial: 17941584
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of botulinum toxin A (BTX‐A) every 3 months to adductors, medial hamstrings, and psoas muscles
Trial: 11717595
Drug: Individualized CVD
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized CVD treatments according to current guidelines
Trial: 9164196
Drug: Standard AC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard AC therapy (4 courses)
Trial: 9164196
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy (same total dose in 2 courses)
Trial: 9164196
Drug: Intensified and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified and increased therapy (total dose doubled)
Trial: 7904106
Drug: Vehicle ointment
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ointment (placebo)
Trial: 3552906
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg tid for two weeks)
Trial: 31169350
Drug: On-treatment AOBPM
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment AOBPM DBP range of 68.6-78.6 mm Hg
Trial: 28378342
Drug: Yoga (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga (12 supervised weekly sessions of 90 min; n=39)
Trial: 21561033
Drug: Transdermal matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal matrix system (100 microg/h)
Trial: 21561033
Drug: Transdermal reservoir
RxNorm normalized name: RESERVOIR,CADD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal reservoir system (100 microg/h)
Trial: 19236443
Drug: RHIIP (6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RHIIP (6.5 mg, 187 IU, inhaled via Cyclohaler DPI)
Trial: 19236443
Drug: SCIns (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCIns (10 IU subcutaneous)
Trial: 16837888
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg/day (group B)
Trial: 16837888
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day (group C)
Trial: 8470415
Drug: Nifedipine (NIF)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (NIF) 2 mg
Trial: 8470415
Drug: Isradipine (ISR)
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine (ISR) 0.5 mg
Trial: 8470415
Drug: Nisoldipine (NIS)
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine (NIS) 0.5 mg
Trial: 8470415
Drug: Felodipine (FEL)
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine (FEL) 0.6 mg
Trial: 3715709
Drug: Accelerated fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated fractionation (total dose 66 Gy, single dose 1.8 to 2 Gy, 1 to 2 fractions daily, total treatment period 4 to 5.5 weeks)
Trial: 3715709
Drug: Accelerated fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated fractionation with treatment period of less than four weeks
Trial: 3715709
Drug: Accelerated fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated fractionation with treatment period of more than five weeks
Trial: 18606504
Drug: Oxycodone (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (10, 20 and 40 mg)
Trial: 18606504
Drug: Hydrocodone (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone (15, 30 and 45 mg)
Trial: 18606504
Drug: Hydromorphone (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (10, 17.5 and 25 mg)
Trial: 17225548
Drug: Qianggan capsule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianggan capsule, 5 granules twice per day for 3 months
Trial: 8581337
Drug: Acetazolamide, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide, 6 mg/kg
Trial: 27450625
Drug: Standard-of-care treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatments
Trial: 27450625
Drug: Monthly e-newsletter
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monthly e-newsletter and communication by SCORE2 Executive Committee
Trial: 24184996
Drug: HHS (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HHS (4 mL/kg)
Trial: 24184996
Drug: HES (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES (7 mL/kg)
Trial: 24184996
Drug: RL (7
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RL (7 mL/kg)
Trial: 12101335
Drug: Laparoscopic shortening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic shortening and plication of uterosacral ligaments with modified Gilliam suspension
Trial: 10431796
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (intact posterior capsule, posterior chamber monofocal IOL)
Trial: 10431796
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (ruptured or removed posterior capsule, anterior chamber monofocal IOL)
Trial: 7653813
Drug: Epinephrine 0.12
RxNorm normalized name: epinephrine 0.125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.12 mg, morphine 0.2 mg, and hyperbaric tetracaine 12 mg intrathecally (EMT group, n = 11)
Trial: 7653813
Drug: Morphine 0.2
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.2 mg and hyperbaric tetracaine 12 mg intrathecally (MT group, n = 13)
Trial: 7653813
Drug: Epinephrine 0.12
RxNorm normalized name: epinephrine 0.125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.12 mg and hyperbaric tetracaine 12 mg intrathecally (ET group, n = 12)
Trial: 2696658
Drug: Jejunal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jejunal infusion of nutrients at 1.3 kcal/min
Trial: 2696658
Drug: Jejunal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jejunal infusion of nutrients at 3.3 kcal/min
Trial: 2696658
Drug: Control (intragastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (intragastric instillation of a 490 kcal, 400 ml, homogenized meal)
Trial: 414267
Drug: Chlorpromazine 25
RxNorm normalized name: chlorpromazine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 25 mg + 95 dBA white noise
Trial: 414267
Drug: Chlorpromazine 75
RxNorm normalized name: chlorproMAZINE 75 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 75 mg + 95 dBA white noise
Trial: 31083198
Drug: Cocktail analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail analgesic injection
Trial: 28511086
Drug: Pipelle biopsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipelle biopsy (twice in the luteal phase prior to IVF)
Trial: 25790229
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI) with 5-fluorouracil plus systemic antineoplastons (A10-I infusion followed by per-oral AS2-1)
Trial: 25790229
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI) with 5-fluorouracil alone (control arm)
Trial: 9043026
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus continuous infusion of 1 g m(‐2) day(‐1) fluorouracil for 5 days
Trial: 9043026
Drug: RT alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT alone (20 Gy in five daily fractions)
Trial: 2022274
Drug: Luteinizing hormone
RxNorm normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone (LH) monitoring scheduling
Trial: 29258584
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tapentadol twice daily
Trial: 29258584
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg tapentadol twice daily
Trial: 29258584
Drug: NSAIDs or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs or paracetamol
Trial: 15978304
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg plus insulin (PIO + INS)
Trial: 15978304
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus insulin (PLB + INS)
Trial: 10486687
Drug: Intraoperative use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative use of narcotic analgesics
Trial: 10369648
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (10 ppm)
Trial: 2984332
Drug: Methylprednisolone, 1
RxNorm normalized name: MethylPREDNISolone, 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone, 1 g intravenously daily for 7 days
Trial: 29627431
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no block treatment)
Trial: 29130615
Drug: In-office bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office bleaching using 40% hydrogen peroxide gel for one hour
Trial: 12399287
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g extruded oat bran (11 g beta-glucan)
Trial: 12399287
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g wheat bran (1 g beta-glucan)
Trial: 2072403
Drug: Individual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual therapy format
Trial: 2072403
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy format
Trial: 2072403
Drug: Inclusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclusion of patient's partner in therapy
Trial: 21355639
Drug: EX/RP therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX/RP therapy
Trial: 21355639
Drug: EX/RP therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX/RP therapy augmented by motivational interviewing strategies
Trial: 17292647
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg codeine